|
Fondaparinux for Thromboembolic Treatment and Prophylaxis of Heparin-Induced Thrombocytopenia (July/August).
Ann Pharmacother. 2006 Jun; [Epub ahead of print] Jun
Efird LE, Kockler DR. |
|
Increased basal platelet activity, plasma adiponectin levels, and diabetes mellitus are associated with poor platelet responsiveness to in vitro effect of aspirin.
Thromb Res. 2006 Jun; [Epub ahead of print] Jun
Takahashi S, Ushida M, Komine R, Shimizu A, Uchida T, Ishihara H, Shibano T, Watanabe G, Ikeda Y, Murata M. |
|
Prevalence of aspirin resistance in patients with an evolving acute myocardial infarction.
Thromb Res. 2006 Jun; [Epub ahead of print] Jun
Poulsen TS, Jorgensen B, Korsholm L, Bjorn Licht P, Haghfelt T, Mickley H. |
|
Effects of argatroban therapy, demographic variables, and platelet count on thrombotic risks in heparin-induced thrombocytopenia.
Chest. 2006 Jun; 129(6):1407-16.
Lewis BE, Wallis DE, Hursting MJ, Levine RL, Leya F. |
|
Evaluation of platelet function in aspirin treated patients with CAD.
J Thromb ThrombolysiS. 2006 Jun; 21(3):241-7.
Williams MS, Kickler TS, Vaidya D, Ng´alla LS, Bush DE. |
|
Argatroban: update.
Am Heart J. 2006 Jun; 151(6):1131-8.
Yeh RW, Jang IK. |
|
Rituximab treatment of thrombotic thrombocytopenic purpura in the setting of connective tissue disease.
J Rheumatol. 2006 Jun; 33(6):1194-6.
Niewold TB, Alpert D, Scanzello CR, Paget SA. |
|
Anagrelide: what was new in 2004 and 2005?
Semin Thromb Hemost. 2006 Jun; 32(4):399-408.
Petrides,PE |
|
Overcoming aspirin resistance: Increased platelet inhibition with combination aspirin and clopidogrel and high dose aspirin therapy in aspirin resistant patients with peripheral vascular disease.
Thromb Haemost. 2006 Jun; 95(6):1042-3. No abstract available. Jun
Wong S, Morel-Kopp MC, Chen Q, Appleberg M, Ward CM, Lewis DR. |
|
Thrombotic end point for assessing argatroban therapy for heparin-induced thrombocytopenia: learning from secondary analyses of prospective studies.
Chest. 2006 Jun; 129(6):1396-8. No abstract available Jun
Warkentin TW. |
|
PIA1/A2 Polymorphism of the Platelet Glycoprotein Receptor IIb/IIIIa and Its Correlation With Myocardial Infarction: an appraisal.
Clin Appl Thromb Hemost. 2006 Jun; 12(1):93-5.
Wiwanitkit V. |
|
Aspirin resistance detected with aggregometry cannot be explained by cyclooxygenase activity: involvement of other signaling pathway(s) in cardiovascular events of aspirin-treated patients.
J Thromb Haemost. 2006 Jun; 4(6):1271-8.
Ohmori T, Yatomi Y, Nonaka T, Kobayashi Y, Madoiwa S, Mimuro J, Ozaki Y, Sakata Y. |
|
Genetic polymorphisms of platelet glycoprotein Ia and the risk for premature myocardial infarction: effects on the release of sCD40L during the acute phase of premature myocardial infarction.
J Am Coll Cardiol. 2006 May; 47(10):1959-66. Epub 2006 Apr 27. Jun
Antoniades C, Tousoulis D, Vasiliadou C, Stefanadi E, Marinou K, Stefanadis C. |
|
Clopidogrel Improves Systemic Endothelial Nitric Oxide Bioavailability in Patients With Coronary Artery Disease. Evidence for Antioxidant and Antiinflammatory Effects.
Arterioscler Thromb Vasc Biol. 2006 May;
Heitzer T, Rudolph V, Schwedhelm E, Karstens M, Sydow K, Ortak M, Tschentscher P, Meinertz T, Boger R, Baldus S. |
|
COX-2 in cardiovascular disease.
Arterioscler Thromb Vasc Biol. 2006 May; 26(5):956-8.
Bishop-Bailey D, Mitchell JA, Warner TD. |
|
Association of platelet glycoprotein Ia polymorphism with minor increase of risk for oral cancer.
Eur J Surg Oncol. 2006 May; 32(4):455-7. Epub 2006 Mar 2. Jun
Vairaktaris E, Yapijakis C, Derka S, Vassiliou S, Serefoglou Z, Vylliotis A, Wiltfang J, Springer I, Nkenke E, Kessler P, Neukam FW. |
|
Aspirin resistance in coronary artery disease is correlated to elevated markers for oxidative stress but not to the expression of cyclooxygenase (COX) 1/2, a novel COX-1 polymorphism or the PlA(1/2) polymorphism.
Platelets.. 2006 May; 17(3):163-9.
Kranzhofer R, Ruef J. |
|
Antithrombotic effects of aspirin based on PLA1/A2 glycoprotein IIIa polymorphism in patients with coronary artery disease.
Thromb Res.. 2006 May; [Epub ahead of print]
Dropinski J, Musial J, Sanak M, Wegrzyn W, Nizankowski R, Szczeklik A. |
|
P2Y12 receptor antagonists: a rapidly expanding group of antiplatelet agents.
Eur Heart J. 2006 May; 27(9):1010-2. Epub 2006 Mar 28 Jun
Cattaneo M. |
|
Platelet interactions with vessel wall components during thrombogenesis.
Blood Cells Mol Dis. 2006 Abr; 36(2):145-7. Epub 2006 Feb 15
Ruggeri ZM. |
